The Medicines and Healthcare products Regulatory Agency (MHRA) on Tuesday authorised a Covid-19 vaccine for infants as young as six months, opening the door
for vaccinating the country's youngest children once the UK's Joint Committee on Vaccination and Immunisation (JCVI) agrees.
The regulator authorised the vaccine - made by Pfizer and BioNTech - for children aged six months to four years old, after it was deemed safe and effective based on
an ongoing clinical trial involving 4,526 participants.
Whether the vaccine is eventually deployed in this age group depends on a recommendation from the JCVI, which advises UK health departments on which shots should be
used as part of the national vaccination programme.
The vaccine is tailored for use in this age group - it is a lower dose version than the one used in children aged five to 11 years. It is given as three injections
in the upper arm, with the first two doses given three weeks apart, followed by a third dose administered at least two months after the second dose.
The UK Health Security Agency (UKHSA) has warned that there has been a continued increase in cases of whooping cough (pertussis) across England since
the start of this year.
According to new data published by the agency on Thursday (7 March), 553 new cases of whooping cough were confirmed in January alone, compared with 858 cases
for the whole of last year (2023).
The country is witnessing a surge in whooping cough cases after a prolonged period of low case numbers, attributed to restrictions and reduced social interaction
during the COVID-19 pandemic. England recorded the highest number of whooping cough cases in 2016, recording 5,949 cases.
As the ongoing rise coincides with a steady decline in the vaccination rates among pregnant women and children, UKHSA has strongly encouraged mums-to-be to get
the maternal pertussis vaccine so that their young baby is protected against this serious disease.